References
- Sanderson H M, Fox S C, Robbins R A, Lo¨ sche W, Spangenberg P, Heptinstall S. Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate forma-tion in whole blood. Platelets 1998; 9: 245–50.
- Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Lo¨ sche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13: 401–6.
- Zhao L, Bath P M, Fox S, May J, Judge H, Lo¨ sche W, Heptinstall S. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003; 19: 178–86.
- Hamburger S, McEver R P. GMP-140 mediates adhe-sion of stimulated platelets to neutrophils. Blood 1990; 75: 550–554.
- Sako D, Chang X J, Barone K M, Vachino G, Shaw G, Veldman T, Bean K M, Furie B, Ahern T J, Cummings D A, Larsen G R. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 1993; 75: 1179–86.
- Chew D P, Bhatt D L, Sapp S, Topol E J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists-A meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201–206.
- Henn V, Slupsky J R, Grafe M. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–4.
- Andre P, Nannizzi-Alaimo L, Prasad S K, Phillips D R. Platelet-derived CD40L: the switch-hitting player of cardio-vascular disease. Circulation 2002; 106: 896–9.
- Jungi T W, Spycher M O, Nydegger U E. Platelet-leukocyte interaction: selective binding of thrombin stimulated platelets to human monocytes, polymorpho-nuclear leukocytes and related cell lines. Blood 1986; 67: 629–36.
- Geng J G, Moore K L, Johnson A E, McEver R P. Neutrophil recognition requires a Ca2þ-induced conformational change in the lectin domain of GMP-140. J Biol Chem 1991; 266: 22313–8.
- Scarborough R M, Kleiman N S, Phillips D R. Platelet glycoprotein IIb/IIIa antagonists-What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999; 100: 437–44.
- Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates coagula-tion via circulating microvesicles and platelets. FASEB J 2003; 17: 476–478.
- Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281: 603–9.
- Miller D L, Yaron R, Yellin M J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998; 63: 373–9.
- Amirkhosravi A, Amaya M, Desai H, Francis J L. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis 2002; 13: 505–12.
- Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322–28.
- Siddiqui F A, Desai H, Amirkhosravi A, Amaya M, Francis J L. The presence and release of tissue factor from human platelets. Platelets 2002; 13: 247–53.
- Camera M, Frigerio C, Marenzi A, Salvioni P, Biglioli E, Tremoli E. Platelet-associated tissue factor expression in patients with unstable coronary artery disease. J Thromb Haemost 2003; 1 (Suppl. 1): Abstract 0C009.
- Scholz T, Temmler U, Krause S, Heptinstall S, Losche W. Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033–8.
- Sarma J, Laan C A, Alam S, Jha A, Fox K A, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166–71.
- Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1–8.
- Camerer E, Kolsto A-B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1–41.
- Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum N O, Forfang K, Froland S S, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina-Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614–20.
- Lee Y, Lee W H, Lee S C, Ahn K J, Choi Y H, Park S W, Lee S H, Seo J D, Park J E. CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology 1999; 92: 11–6.
- Mach F, Schonbeck U, Sukhova G K, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200–3.
- Furman M I, Barnard M R, Krueger L A, Fox M L, Shilale E A, Lessard D M, Marchese P, Frelinger A L, Goldberg R J, Michelson A D. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002–6.
- Michelson A D, Barnard M R, Krueger L A, Valeri C R, Furman M I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin-Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533–37.